Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine

Science

Volumn 277, Issue 5328, 1997, Pages 953-955

  Jentsch, J David ^a   Redmond Jr , D Eugene ^a   Elsworth, John D ^a   Taylor, Jane R ^a   Youngren, Kenneth D ^a   Roth, Robert H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR DISORDER; BRAIN DYSFUNCTION; COGNITIVE DEFECT; CONTROLLED STUDY; INTRAMUSCULAR DRUG ADMINISTRATION; MONKEY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CERCOPITHECUS AETHIOPS; CLOZAPINE; COGNITION; DISEASE MODELS, ANIMAL; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; PHENCYCLIDINE; PREFRONTAL CORTEX; SCHIZOPHRENIA; TIME FACTORS;

ANIMALIA; CERCOPITHECUS;

EID: 0030862672     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.277.5328.953     Document Type: Article

References (48)

1. D. C. Javitt and S. R. Zukin, Am. J. Psychiatry 148, 13C1 (1991).
2. A. S. Carlin, I. Grant, K. M. Adams, R. Reed, Am. J. Drug Alcohol Abuse 6, 273 (1979); J. E. Lewis and R. B. Hordan, in Phencyclidine: An Update, R. C. Petersen and R. C. Stillman, Eds. (National Institute of Drug Abuse, Rockville, MD, 1986), p. 66; J. Cosgrove and T. G. Newell, J. Clin. Psychol. 47, 159 (1991).
3. A. S. Carlin, I. Grant, K. M. Adams, R. Reed, Am. J. Drug Alcohol Abuse 6, 273 (1979); J. E. Lewis and R. B. Hordan, in Phencyclidine: An Update, R. C. Petersen and R. C. Stillman, Eds. (National Institute of Drug Abuse, Rockville, MD, 1986), p. 66; J. Cosgrove and T. G. Newell, J. Clin. Psychol. 47, 159 (1991).
4. A. S. Carlin, I. Grant, K. M. Adams, R. Reed, Am. J. Drug Alcohol Abuse 6, 273 (1979); J. E. Lewis and R. B. Hordan, in Phencyclidine: An Update, R. C. Petersen and R. C. Stillman, Eds. (National Institute of Drug Abuse, Rockville, MD, 1986), p. 66; J. Cosgrove and T. G. Newell, J. Clin. Psychol. 47, 159 (1991).
5. H. Klonhoff, H. C. Fibiger, G. H. Hutton, J. Nerv. Ment. Dis. 150, 291 (1970); S. Levin, J. Psychiatr. Res. 18, 27 (1984); T. E. Goldberg and J. M. Gold, in Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom and D. J. Kupfer, Eds. (Raven, New York, 1995), p. 1245.
6. H. Klonhoff, H. C. Fibiger, G. H. Hutton, J. Nerv. Ment. Dis. 150, 291 (1970); S. Levin, J. Psychiatr. Res. 18, 27 (1984); T. E. Goldberg and J. M. Gold, in Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom and D. J. Kupfer, Eds. (Raven, New York, 1995), p. 1245.
7. H. Klonhoff, H. C. Fibiger, G. H. Hutton, J. Nerv. Ment. Dis. 150, 291 (1970); S. Levin, J. Psychiatr. Res. 18, 27 (1984); T. E. Goldberg and J. M. Gold, in Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom and D. J. Kupfer, Eds. (Raven, New York, 1995), p. 1245.
8. E. T. Fey, J. Consult. Psychol. 15, 311 (1951); T. Shallice, P. W. Burgess, C. D. Frith, Psychol. Med. 21, 661 (1991).
9. E. T. Fey, J. Consult. Psychol. 15, 311 (1951); T. Shallice, P. W. Burgess, C. D. Frith, Psychol. Med. 21, 661 (1991).
10. P. S. Goldman-Rakic, in Handbooks of Physiology, The Nervous System, vol. V, F. Plum and V. M. Mountcastle, Eds. (American Physiological Society, Bethesda, MD, 1987), p. 373.
11. B. Milner, Arch. Neurol. 9, 100 (1963); M. Freedman and M. Oscar-Berman, Behav. Neurosci. 100, 337 (1986); P. S. Goldman-Rakic, in Psychopathology and the Brain, B. J. Carroll and J. E. Barrett, Eds. (Raven, New York, 1991), p. 1; S. Park and P. S. Holzman, Arch. Gen. Psychiatry 49, 975 (1992); R. M. Ridley, B. A. Clark, L. J. Dunford, H. F. Baker, Neuroscience 52, 595 (1993); A. M. Owen, A. C. Roberts, J. R. Hodges, B. A. Summers, Brain 116, 1159 (1993).
12. B. Milner, Arch. Neurol. 9, 100 (1963); M. Freedman and M. Oscar-Berman, Behav. Neurosci. 100, 337 (1986); P. S. Goldman-Rakic, in Psychopathology and the Brain, B. J. Carroll and J. E. Barrett, Eds. (Raven, New York, 1991), p. 1; S. Park and P. S. Holzman, Arch. Gen. Psychiatry 49, 975 (1992); R. M. Ridley, B. A. Clark, L. J. Dunford, H. F. Baker, Neuroscience 52, 595 (1993); A. M. Owen, A. C. Roberts, J. R. Hodges, B. A. Summers, Brain 116, 1159 (1993).
13. B. Milner, Arch. Neurol. 9, 100 (1963); M. Freedman and M. Oscar-Berman, Behav. Neurosci. 100, 337 (1986); P. S. Goldman-Rakic, in Psychopathology and the Brain, B. J. Carroll and J. E. Barrett, Eds. (Raven, New York, 1991), p. 1; S. Park and P. S. Holzman, Arch. Gen. Psychiatry 49, 975 (1992); R. M. Ridley, B. A. Clark, L. J. Dunford, H. F. Baker, Neuroscience 52, 595 (1993); A. M. Owen, A. C. Roberts, J. R. Hodges, B. A. Summers, Brain 116, 1159 (1993).
14. B. Milner, Arch. Neurol. 9, 100 (1963); M. Freedman and M. Oscar-Berman, Behav. Neurosci. 100, 337 (1986); P. S. Goldman-Rakic, in Psychopathology and the Brain, B. J. Carroll and J. E. Barrett, Eds. (Raven, New York, 1991), p. 1; S. Park and P. S. Holzman, Arch. Gen. Psychiatry 49, 975 (1992); R. M. Ridley, B. A. Clark, L. J. Dunford, H. F. Baker, Neuroscience 52, 595 (1993); A. M. Owen, A. C. Roberts, J. R. Hodges, B. A. Summers, Brain 116, 1159 (1993).
15. B. Milner, Arch. Neurol. 9, 100 (1963); M. Freedman and M. Oscar-Berman, Behav. Neurosci. 100, 337 (1986); P. S. Goldman-Rakic, in Psychopathology and the Brain, B. J. Carroll and J. E. Barrett, Eds. (Raven, New York, 1991), p. 1; S. Park and P. S. Holzman, Arch. Gen. Psychiatry 49, 975 (1992); R. M. Ridley, B. A. Clark, L. J. Dunford, H. F. Baker, Neuroscience 52, 595 (1993); A. M. Owen, A. C. Roberts, J. R. Hodges, B. A. Summers, Brain 116, 1159 (1993).
16. B. Milner, Arch. Neurol. 9, 100 (1963); M. Freedman and M. Oscar-Berman, Behav. Neurosci. 100, 337 (1986); P. S. Goldman-Rakic, in Psychopathology and the Brain, B. J. Carroll and J. E. Barrett, Eds. (Raven, New York, 1991), p. 1; S. Park and P. S. Holzman, Arch. Gen. Psychiatry 49, 975 (1992); R. M. Ridley, B. A. Clark, L. J. Dunford, H. F. Baker, Neuroscience 52, 595 (1993); A. M. Owen, A. C. Roberts, J. R. Hodges, B. A. Summers, Brain 116, 1159 (1993).
17. M. Hertzman, R. C. Reba, E. V. Kotlyarove, Am. J. Psychiatry 147, 255 (1990); J. C. Wu, M. S. Buchsbaum, W. E. Bunney, Jpn. J. Psychopharmacol. 11, 47 (1991).
18. M. Hertzman, R. C. Reba, E. V. Kotlyarove, Am. J. Psychiatry 147, 255 (1990); J. C. Wu, M. S. Buchsbaum, W. E. Bunney, Jpn. J. Psychopharmacol. 11, 47 (1991).
19. B. G. Bunney, W. E. Bunney, A. Carlsson, in Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom and D. J. Kupfer, Eds. (Raven, New York, 1995), p. 1205.
20. T. J. Brozoski, R. M. Brown, H. E. Rosvold, P. S. Goldman, Science 205, 929 (1979); T. Sawaguchi and P. S. Goldman-Rakic, ibid. 251, 947 (1991).
21. T. J. Brozoski, R. M. Brown, H. E. Rosvold, P. S. Goldman, Science 205, 929 (1979); T. Sawaguchi and P. S. Goldman-Rakic, ibid. 251, 947 (1991).
22. J. R. Taylor, J. D. Elsworth, R. H. Roth, J. R. Sladek, D. E. Redmond Jr., Brain 113, 617 (1990); J. R. Taylor, R. H. Roth, J. R. Sladek, D. E. Redmond Jr., Behav. Neurosci. 104, 564 (1990); J. D. Elsworth, A. Y. Deuten, D. E. Redmond Jr., J. R. Sladek, R. H. Roth, Neurosci. Lett. 114, 316 (1990).
23. J. R. Taylor, J. D. Elsworth, R. H. Roth, J. R. Sladek, D. E. Redmond Jr., Brain 113, 617 (1990); J. R. Taylor, R. H. Roth, J. R. Sladek, D. E. Redmond Jr., Behav. Neurosci. 104, 564 (1990); J. D. Elsworth, A. Y. Deuten, D. E. Redmond Jr., J. R. Sladek, R. H. Roth, Neurosci. Lett. 114, 316 (1990).
24. J. R. Taylor, J. D. Elsworth, R. H. Roth, J. R. Sladek, D. E. Redmond Jr., Brain 113, 617 (1990); J. R. Taylor, R. H. Roth, J. R. Sladek, D. E. Redmond Jr., Behav. Neurosci. 104, 564 (1990); J. D. Elsworth, A. Y. Deuten, D. E. Redmond Jr., J. R. Sladek, R. H. Roth, Neurosci. Lett. 114, 316 (1990).
25. Monkeys were trained and tested on the object retrieval with a detour task as described (10). Animals were treated with sterile saline (0.1 ml/kg twice a day, intramuscularly) or phencyclidine (0.3 mg/kg twice a day, intramuscularly) for 2 weeks. Two days after cessation of drug treatment, they began training on the task with an experimenter who was unaware of their drug treatment. Performance assessments and drug challenges were made no less than 7 days after cessation of drug treatment.
26. A. Diamond, in Thought Without Language, L. Weiskrantz, Ed. (Clarendon, Oxford, 1988), p. 337; A. Diamond, S. Zola-Morgan, L. Squire, Behav. Neurosci. 102, 526 (1989).
27. A. Diamond, in Thought Without Language, L. Weiskrantz, Ed. (Clarendon, Oxford, 1988), p. 337; A. Diamond, S. Zola-Morgan, L. Squire, Behav. Neurosci. 102, 526 (1989).
28. J. D. Jentsch, J. D. Elsworth, D. E. Redmond Jr., R. H. Roth, J. Neurosci. 17, 1769 (1997).
29. J. D. Jentsch, A. Tran, D. Le, K. D. Youngren, R. H. Roth, Neuropsychopharmacology 17, 92 (1997).
30. B. Angrist, E. Peselow, M. Rubinstein, J. Corwin, J. Rotrosen, Psychopharmacology 78, 128 (1982); D. G. Daniel and K. F. Berman, J. Neuropsychiatry 1, 377 (1989); D. G. Daniel et al., J. Neurosci. 11, 1907 (1991); R. J. Dolan et al. Nature 378, 180 (1995).
31. B. Angrist, E. Peselow, M. Rubinstein, J. Corwin, J. Rotrosen, Psychopharmacology 78, 128 (1982); D. G. Daniel and K. F. Berman, J. Neuropsychiatry 1, 377 (1989); D. G. Daniel et al., J. Neurosci. 11, 1907 (1991); R. J. Dolan et al. Nature 378, 180 (1995).
32. B. Angrist, E. Peselow, M. Rubinstein, J. Corwin, J. Rotrosen, Psychopharmacology 78, 128 (1982); D. G. Daniel and K. F. Berman, J. Neuropsychiatry 1, 377 (1989); D. G. Daniel et al., J. Neurosci. 11, 1907 (1991); R. J. Dolan et al. Nature 378, 180 (1995).
33. B. Angrist, E. Peselow, M. Rubinstein, J. Corwin, J. Rotrosen, Psychopharmacology 78, 128 (1982); D. G. Daniel and K. F. Berman, J. Neuropsychiatry 1, 377 (1989); D. G. Daniel et al., J. Neurosci. 11, 1907 (1991); R. J. Dolan et al. Nature 378, 180 (1995).
34. P. Karlsson et al., Psychopharmacology 121, 309 (1995).
35. T. E. Goldberg et al., Br. J. Psychiatry 163, 43 (1993); T. E. Goldberg and D. R. Weinberger, J. Clin. Psychiatry 55 (suppl. B), 88 (1994).
36. T. E. Goldberg et al., Br. J. Psychiatry 163, 43 (1993); T. E. Goldberg and D. R. Weinberger, J. Clin. Psychiatry 55 (suppl. B), 88 (1994).
37. J. Kane, G. Honigfeld, J. Singer, H. Y. Meltzer, Arch. Gen. Psychiatry 45, 789 (1988); M. A. Lee, P. A. Thompson, H. Y. Meltzer, J. Clin. Psychiatry 55 (no. 9) (suppl. B), 82 (1994).
38. J. Kane, G. Honigfeld, J. Singer, H. Y. Meltzer, Arch. Gen. Psychiatry 45, 789 (1988); M. A. Lee, P. A. Thompson, H. Y. Meltzer, J. Clin. Psychiatry 55 (no. 9) (suppl. B), 82 (1994).
39. Clozapine (1 mg/kg per day, intramuscularly) was administered for 3 consecutive days beginning on day 10 after cessation of PCP treatment. Performance was assessed before and 2 hours after final treatment with clozapine.
40. B. Saletu, J. Grunberger, L. Linzmayer, Pharmacopsychiatry 20, 12 (1987); B. L. Murphy, R. H. Roth, A. F. T. Arnsten, Neuropsychopharmacology 16, 433 (1997).
41. B. Saletu, J. Grunberger, L. Linzmayer, Pharmacopsychiatry 20, 12 (1987); B. L. Murphy, R. H. Roth, A. F. T. Arnsten, Neuropsychopharmacology 16, 433 (1997).
42. K. D. Youngren, B. Moghaddam, B. S. Bunney, R. H. Roth, Neurosci. Lett. 165, 41 (1994); K. D. Youngren et al., Soc. Neurosci. Abstr. 21, 1705 (1995).
43. K. D. Youngren, B. Moghaddam, B. S. Bunney, R. H. Roth, Neurosci. Lett. 165, 41 (1994); K. D. Youngren et al., Soc. Neurosci. Abstr. 21, 1705 (1995).
44. D. R. Weinberger, K. F. Berman, B. P. Illowsky, Arch. Gen. Psychiatry 45, 609 (1988); K. L. Davis, R. S. Kahn, G. Ko, M. Davidson, Am. J. Psychiatry 148, 11 (1991); T. W. Robbins, Schizophr. Bull. 16, 391 (1990); A. Y. Deutch, J. Neural Transm. Suppl. 36, 61 (1992).
45. D. R. Weinberger, K. F. Berman, B. P. Illowsky, Arch. Gen. Psychiatry 45, 609 (1988); K. L. Davis, R. S. Kahn, G. Ko, M. Davidson, Am. J. Psychiatry 148, 11 (1991); T. W. Robbins, Schizophr. Bull. 16, 391 (1990); A. Y. Deutch, J. Neural Transm. Suppl. 36, 61 (1992).
46. D. R. Weinberger, K. F. Berman, B. P. Illowsky, Arch. Gen. Psychiatry 45, 609 (1988); K. L. Davis, R. S. Kahn, G. Ko, M. Davidson, Am. J. Psychiatry 148, 11 (1991); T. W. Robbins, Schizophr. Bull. 16, 391 (1990); A. Y. Deutch, J. Neural Transm. Suppl. 36, 61 (1992).
47. D. R. Weinberger, K. F. Berman, B. P. Illowsky, Arch. Gen. Psychiatry 45, 609 (1988); K. L. Davis, R. S. Kahn, G. Ko, M. Davidson, Am. J. Psychiatry 148, 11 (1991); T. W. Robbins, Schizophr. Bull. 16, 391 (1990); A. Y. Deutch, J. Neural Transm. Suppl. 36, 61 (1992).
48. We thank P. S. Goldman-Rakic for critical reading of this manuscript; M. B. Bowers, B. S. Bunney, A. Y. Deutch, G. R. Heninger, and J. F. Tallman for helpful commentary; and A. Tran, Y. Pan, and the staff of the St. Kitts Biomedical Research Foundation for technical support. Supported in part by Public Health Service awards MH14092 and MH44866 (R.H.R.); by the Scottish Rite Schizophrenia Research Program NMJ, USA (J.D.J.); by RSA K05-MH00643 (D.E.R.); and by the Axion Research Foundation.